Targeting nerve growth factor in pain: what is the therapeutic potential?
about
Anti-nerve growth factor in pain management: current evidenceNerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain managementNeurotrophins and Neuropathic Pain: Role in PathobiologyRepeated muscle injury as a presumptive trigger for chronic masticatory muscle painSingle cycle structure-based humanization of an anti-nerve growth factor therapeutic antibodyMechanisms of nerve growth factor signaling in bone nociceptors and in an animal model of inflammatory bone pain.Chronic Social Stress Time-Dependently Affects Neuropathic Pain-Related Cold Allodynia and Leads to Altered Expression of Spinal Biochemical Mediators.Nerve growth factor (NGF) regulates activity of nuclear factor of activated T-cells (NFAT) in neurons via the phosphatidylinositol 3-kinase (PI3K)-Akt-glycogen synthase kinase 3β (GSK3β) pathwayAccumulation of nerve growth factor and its receptors in the uterus and dorsal root ganglia in a mouse model of adenomyosisOpioid pharmaceuticals and addiction: the issues, and research directions seeking solutions.Antagonism of nerve growth factor-TrkA signaling and the relief of painPotential mechanisms for hypoalgesia induced by anti-nerve growth factor immunoglobulin are identified using autoimmune nerve growth factor deprivation.Predictive validity of behavioural animal models for chronic painA Surface Plasmon Resonance Spectroscopy Method for Characterizing Small-Molecule Binding to Nerve Growth Factor.Design and nuclear magnetic resonance (NMR) structure determination of the second extracellular immunoglobulin tyrosine kinase A (TrkAIg2) domain construct for binding site elucidation in drug discovery.Multiple orbital neurofibromas, painful peripheral nerve tumors, distinctive face and marfanoid habitus: a new syndrome.Tanezumab for Patients with Osteoarthritis of the Knee: A Meta-Analysis.Monoclonal antibodies for the treatment of osteoarthritis.Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects.Efficacy and Safety of Tanezumab on Osteoarthritis Knee and Hip Pains: A Meta-Analysis of Randomized Controlled Trials.Protective Effects of Alisma orientale Extract against Hepatic Steatosis via Inhibition of Endoplasmic Reticulum Stress.Mast Cell-Mediated Mechanisms of Nociception.4α-phorbol 12,13-didecanoate activates cultured mouse dorsal root ganglia neurons independently of TRPV4Population pharmacokinetics of tanezumab in phase 3 clinical trials for osteoarthritis pain.Translational pain research: achievements and challengesThe fundamental unit of pain is the cell.The efficacy of nerve growth factor antibody in a mouse model of neuropathic cancer pain.Augmenting glial cell-line derived neurotrophic factor signaling to treat painful neuropathies.Structural characterization of nonactive site, TrkA-selective kinase inhibitors.Nerve growth factor inhibition with tanezumab influences weight-bearing and subsequent cartilage damage in the rat medial meniscal tear model.Nerve growth factor signaling in prostate health and disease.Nerve growth factor, pain, itch and inflammation: lessons from congenital insensitivity to pain with anhidrosis.The discovery and development of analgesics: new mechanisms, new modalities.Perineural invasion and associated pain in pancreatic cancer.Recent advances in the pharmaceutical management of pain.The role of nerve growth factor in the prophylaxis and treatment of diabetic foot ulcersManagement of cancer pain: 1. Wider implications of orthodox analgesics.New investigational drugs for the treatment of neuropathic pain.Expert opinion on emerging drugs: chronic low back pain.Nociception and role of immune system in pain.
P2860
Q26746194-A7C016DE-AC80-4E74-B9E5-0D7D84D6C785Q27011486-45B711A8-30F7-49D5-BACA-3055509B4CDDQ28084413-493B0225-6208-4326-B0ED-AF69E712BC71Q28392760-7F58106D-7037-4C68-A3A7-7E5088B41B7CQ28731515-D91DC01B-4573-4A8A-BB08-8FB7BFE85C75Q33610520-821E352C-ACB6-43D0-A082-E6DE84E9CC6BQ33650202-8C893580-2468-478C-951F-EDB4C9010AB1Q34467607-DC63BD61-885C-4807-A4AE-8CFDCE724542Q34708447-30BE3F3A-7945-4E86-AF79-2D30AB1CA725Q34773536-7CD8A60F-DF76-4559-86D8-A85CF4865A96Q35064559-7C451E88-B540-4FAC-A223-77E78EE0E1FFQ35463321-2FE24D1B-4ABE-4814-A846-7953DC23E03FQ35589944-356768B5-095F-4B79-BD27-D6CD2D1D9439Q35794076-3E90785A-CE21-4A22-B1E3-37807255989FQ35858432-8D85584A-51E2-4F99-8A27-66B9A9CFE477Q35969099-FA812B66-5354-453A-A6C9-4D72209F2467Q36050186-B891BBF3-8024-4333-AC14-6C0C796C5BC7Q36113839-4057A598-3217-47D4-A9EF-1630F5C4A8DFQ36141039-F8B6FF5F-F579-41EC-A16C-297B296CEB75Q36236043-7494D746-C86A-4D98-AE95-6BCDF277D46EQ36324486-79157E40-8AA4-4EF8-9E0A-3F3B4B403AB9Q36404141-950879C8-194D-45CE-90ED-3446297B84E8Q36629305-9C194BE4-1B1C-4DB5-992C-C4DAF999FA75Q36706795-9AC681D9-EAF3-4A7A-B30B-7BD7F8356E61Q37376539-2E9AE313-1216-44D9-9EB2-B75A0C76383CQ37381403-3DFDBD98-1A27-4AB0-B47D-BE0796409A07Q37418193-D721F83A-6574-485B-BC68-9B507DB78649Q37587729-E385547D-A079-45E6-9592-FBDF3412D9E6Q37599025-8E577E29-4A58-4033-A8F1-30FB77D389EEQ37604491-C855B544-556D-48E9-91B6-A30FF3740DCCQ37694590-E31BAF78-C6F4-43E4-9DAC-9C17DABEFCE3Q37803223-9DB64ADE-0E95-4B48-98DB-8ADEB9D1214CQ37805995-704D302C-6E3D-4EB7-B41A-BA167BF0890AQ37937421-8572A74A-E5AA-4074-A8F9-5B3C6EACE894Q37960192-6D1F6D3B-07F3-4279-A0D2-61F7D743A1ECQ38038613-9B3878CC-9DF4-4544-9876-9C2A48CDBBDBQ38182562-3CDFE157-D741-488F-9E81-8CEFD864F30DQ38217614-79AB1627-25F5-4C95-B37F-7D5AF595320FQ38292223-ADC4A399-D2C8-407E-9092-E1F851CDC02AQ38303334-BE769FFF-F392-48AB-B681-7807E453DC1C
P2860
Targeting nerve growth factor in pain: what is the therapeutic potential?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting nerve growth factor in pain: what is the therapeutic potential?
@en
Targeting nerve growth factor in pain: what is the therapeutic potential?
@nl
type
label
Targeting nerve growth factor in pain: what is the therapeutic potential?
@en
Targeting nerve growth factor in pain: what is the therapeutic potential?
@nl
prefLabel
Targeting nerve growth factor in pain: what is the therapeutic potential?
@en
Targeting nerve growth factor in pain: what is the therapeutic potential?
@nl
P1433
P1476
Targeting nerve growth factor in pain: what is the therapeutic potential?
@en
P2093
David Dawbarn
Judy J Watson
P2860
P304
P356
10.2165/0063030-200822060-00002
P577
2008-01-01T00:00:00Z
P6179
1034924322